以改善预后为目标的难治性支原体肺炎治疗策略

Treatment strategy for refractory mycoplasma pneumonia aiming at improving prognosis

肺炎支原体（MP）是儿童和青少年社区获得性肺炎中常见病原体之一。因MP感染引起的肺炎称为肺炎支原体肺炎（MPP）,约占儿童社区获得性肺炎的15%-50%。一般来说,肺炎支原体感染具有自限性,经大环内酯类药物治疗后临床预后良好。但近年来,临床上出现了肺部病变严重的MPP,并可影响全身多个器官、造成严重后果,甚至发生致死的难治性支原体肺炎（RMPP）。如何早期诊断和有效地治疗RMPP,减少其后遗症的发生,已成为目前关注的热点。本文将重点阐述如何早期诊断并及时处理RM-PP,以改善其预后。

Mycoplasma pneumoniae（MP）is one of the main pathogens causing community-acquired pneumonia in paediatrics and teens.Mycoplasma pneumoniae pneumonia（MPP）,which is caused by MP,accounted for community-acquired pneumonia in children in 15% to 50%. The infection of MP is usually a self-limited disease,and Macrolides are considered the first-choice medicine.But in recent years, we found some severe MPP, which Can affect multiple body organs, developing in serious consequences, even fatal. These cases are called refractory mycoplcasma pneumoniae pneumonia（RMPP）.The early diagnosis and treatment of RMPP has become the focus of attention.This article will focus on the early diagnosis and treatment of RMPP,in order to Improve the prognosis.